Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release- ‘Zaynich™ (Zidebactam/Cefepime, WCK 5222) enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme-drug resistant Gram negative pathogens’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.
The above information is a part of company’s filings submitted to BSE.